Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Targovax Pivots Towards Oncolytic Viruses

Executive Summary

Oncolytic virus-based therapies which act as immune activators will be the only candidates in the Norwegian biotech’s pipeline from now on.

 

You may also be interested in...



AZ Targets Viral Oncolytics With Transgene Development Deal

AstraZeneca inks a deal with French firm Transgene to co-develop five armed oncolytic vaccinia virus candidates in an area that is hotting up for big pharma.

Targovax Adjusts Clinical Pipeline After ASCO Disrupts TG Vaccine Program

Targovax terminates development of TG01 in pancreatic cancer patients after data unveiled at ASCO fundamentally alters development preconditions for its TG vaccine program.

Job Cuts As Polyphor Focuses On First-In-Class Anticancer

Switzerland’s Polyphor has redefined its business strategy and is aiming to become a leaner organization, with a potential first-in-class immuno-oncologic, balixafortide, in late-stage clinical development for breast cancer.

 

Topics

Related Companies

UsernamePublicRestriction

Register

SC125278

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel